Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Golimumab Mazumdar S; Greenwald DMAbs 2009[Sep]; 1 (5): 422-31Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.|*Antibodies, Monoclonal/administration & dosage/adverse effects/immunology/therapeutic use[MESH]|*Arthritis, Psoriatic/drug therapy/immunology[MESH]|*Arthritis, Rheumatoid/drug therapy/immunology[MESH]|*Spondylitis, Ankylosing/drug therapy/immunology[MESH]|Animals[MESH]|Clinical Trials as Topic[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Therapy, Combination[MESH]|Female[MESH]|Humans[MESH]|Infant, Newborn[MESH]|Male[MESH]|Methotrexate/administration & dosage/therapeutic use[MESH]|Pregnancy[MESH]|Treatment Outcome[MESH]|Tumor Necrosis Factor-alpha/*immunology[MESH] |